Akero Therapeutics, Inc. (AKRO) Stock

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.

Akero Therapeutics, Inc. is headquartered in US.

Akero Therapeutics, Inc. (AKRO) stock trades at $54.65 with a market capitalization of $4.50B. The stock is valued at a negative price-to-earnings (P/E) ratio of -19.87, reflecting a net loss over the last twelve months, price-to-book of 4.68, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $21.34 and $58.40, and currently trades 6.4% below its 52-week high.

On profitability, Akero Therapeutics, Inc. generates a return on equity (ROE) of -21.79% (negative, reflecting a net loss), return on capital employed of -26.31%.

Official website: www.akerotx.com

Akero Therapeutics, Inc. by the numbers, 2017–2024

Between 2017 and 2024 Akero Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-252.0M.

On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-294.0M.

Borrowings stand at $36.0M, cash on hand is $737.8M, cash from operations was $-230.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -37.3% over five years, and was -33.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Akero Therapeutics, Inc. (AKRO) — frequently asked questions